ProQR Therapeutics N.V. (PRQR) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, gaining 1.5% versus a loss of 49.5%. Over five years, PRQR leads with a -85.5% price change compared with -98.2% for ZNTL. ProQR Therapeutics N.V. is the larger company by market cap ($147.0 million vs $133.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRQR | ZNTL |
|---|---|---|
| Share price | $1.04 | $1.36 |
| Market cap | $146.98M | $133.64M |
| 1-day change | -0.95% | 0.00% |
| YTD return | -48.51% | +0.74% |
| 1-year return | -49.51% | +1.49% |
| 5-year return | -85.54% | -98.21% |
| EPS (TTM) | $-0.43 | $-1.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | — | $-137.06M |
| 52-week high | $2.49 | $6.95 |
| 52-week low | $1.00 | $1.30 |
| Distance from 52-week high | -58.15% | -80.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +626.92% | +447.06% |
| Average volume | 793.64K | 1.26M |
| Shares outstanding | 141.33M | 98.27M |
| Employees | 186 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed PRQR by 51.0 percentage points over the past year.
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
PRQR vs ZNTL FAQ
Which is bigger, ProQR Therapeutics N.V. or Zentalis Pharmaceuticals?
ProQR Therapeutics N.V. (PRQR) is larger, with a market capitalization of $146.98M compared with $133.64M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, PRQR or ZNTL?
ZNTL returned +1.49% over the past 12 months, compared with -49.51% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are ProQR Therapeutics N.V. and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.